Is the priority review voucher program stimulating new drug development for tropical diseases?

Congress created the tropical disease priority review voucher program to stimulate new drug development for tropical diseases. An analysis of the pharmaceutical pipeline indicates that the development of drugs for these tropical diseases has increased. However, the effects of the program are not uni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PLoS neglected tropical diseases 2018-08, Vol.12 (8), p.e0006695-e0006695
Hauptverfasser:	Kerr, Kirk W, Henry, Thomas C, Miller, Kathleen L
Format:	Artikel
Sprache:	eng
Schlagworte:	Care and treatment Development and progression Diseases Drug Approval - legislation & jurisprudence Drug development Drug discovery Drug Discovery - legislation & jurisprudence Drug Discovery - trends Drug Industry - trends Drugs FDA approval Food Human diseases Humans Infectious diseases Laws, regulations and rules Malaria Medicine and Health Sciences Pediatrics Pharmaceutical industry Pharmaceuticals Prices Public health Submarine pipelines Trends Tropical climate Tropical diseases Tropical Medicine Tuberculosis United States United States Food and Drug Administration - legislation & jurisprudence United States Food and Drug Administration - trends Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Congress created the tropical disease priority review voucher program to stimulate new drug development for tropical diseases. An analysis of the pharmaceutical pipeline indicates that the development of drugs for these tropical diseases has increased. However, the effects of the program are not uniform across all diseases, as malaria and tuberculosis have seen significant new drug development, while other diseases have not.
ISSN:	1935-2735 1935-2727 1935-2735
DOI:	10.1371/journal.pntd.0006695